3Thomas C. Mayer S, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation[J]. Neurology,1997, 48(5):1253-1260.
4Mayer S. Intensive care of the myasthenic patient[J].Neurology, 1997, 48(suppl 5): s70-75.
5Berrouschot J. Baumann I, Kalischewski P, et al.Therapy of myasthenic crisis [J]. Crit Care Med,1997,25(7):1228-1235.
6Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care[J]. Semin Neurol,2004, 24(1):75-81.
7Howard JF. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis[J]. Neurology. 1998. 51(6):S30-36.
8Bedla CK, Sanders DB. On concept of myasthenic crisis[J]. J Clin Neuromusc Dis, 2002, 4(1):40-42.
9Gajdos PH. Contributiong of intravenous immunoglobulins to treatment of MG[J]. Ann Med Interne(Paris). 2002, 151(suppl 1):s130-134.
10Raphael JC, Annane D, Chevret S, et al. Respective indications of plasma exchange and hige-dose immunoglobulins in polyradiculoneuritis and myasthenia gravis[J]. Presse Med, 1996, 25(31): 1516-1522.
